CIK 0001774857 · <br>Emerging growth company
Aardvark Therapeutics, Inc.
Sign in to watch- Ticker
- AARD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 821606367
- Phone
- (858) 225-7696
- Business address
- 4370 LA JOLLA VILLAGE DRIVE, SUITE 1050, SAN DIEGO, CA, 92122
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $394,957
- in 1 filing, $395K under 10b5-1 plans
Net −$394,957. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-06 | Lee Tien-Li Chief Executive Officer | Grant or award · Stock Option (right to buy) | +203,851 | 203,851 | ||
| 2026-11-06 | Lee Tien-Li Chief Executive Officer | Returned to the company · Stock Option (right to buy) | −203,851 | 0 | ||
| 2026-11-06 | Lee Tien-Li Chief Executive Officer | Grant or award · Stock Option (right to buy) | +549,534 | 549,534 | ||
| 2026-11-06 | Lee Tien-Li Chief Executive Officer | Returned to the company · Stock Option (right to buy) | −549,534 | 0 | ||
| 2026-11-06 | Lee Tien-Li Chief Executive Officer | Grant or award · Stock Option (right to buy) | +40,566 | 40,566 | ||
| 2026-11-06 | Lee Tien-Li Chief Executive Officer | Returned to the company · Stock Option (right to buy) | −40,566 | 0 | ||
| 2026-11-06 | Sun Nelson See Remarks | Grant or award · Stock Option (right to buy) | +70,549 | 70,549 | ||
| 2026-11-06 | Sun Nelson See Remarks | Returned to the company · Stock Option (right to buy) | −70,549 | 0 | ||
| 2026-11-06 | Sun Nelson See Remarks | Grant or award · Stock Option (right to buy) | +209,826 | 209,826 | ||
| 2026-11-06 | Sun Nelson See Remarks | Returned to the company · Stock Option (right to buy) | −209,826 | 0 | ||
| 2026-11-06 | Sun Nelson See Remarks | Grant or award · Stock Option (right to buy) | +23,719 | 23,719 | ||
| 2026-11-06 | Sun Nelson See Remarks | Returned to the company · Stock Option (right to buy) | −23,719 | 0 | ||
| 2026-11-06 | Jaiman Manasi Chief Medical Officer | Grant or award · Stock Option (right to buy) | +70,549 | 70,549 | ||
| 2026-11-06 | Jaiman Manasi Chief Medical Officer | Returned to the company · Stock Option (right to buy) | −70,549 | 0 | ||
| 2026-11-06 | Jaiman Manasi Chief Medical Officer | Grant or award · Stock Option (right to buy) | +126,999 | 126,999 | ||
| 2026-11-06 | Jaiman Manasi Chief Medical Officer | Returned to the company · Stock Option (right to buy) | −126,999 | 0 | ||
| 2026-11-06 | Jaiman Manasi Chief Medical Officer | Grant or award · Stock Option (right to buy) | +177,012 | 177,012 | ||
| 2026-11-06 | Jaiman Manasi Chief Medical Officer | Returned to the company · Stock Option (right to buy) | −177,012 | 0 | ||
| 2026-10-07 | Zhang Zhongwei Director | Grant or award · Stock Option (right to buy) | +127,061 | 127,061 | ||
| 2026-09-11 | Sun Nelson See Remarks | Sale 10b5-1 | −62,000 | $5.18 | $321K | 35,475 |
Page 1 of 4 · 71 trades